AI in the drug discovery industry

Out now in Innovations in Pharmaceutical Technology, Optibrium’s Global Head of Application Science and President of Optibrium Inc, Dr Tamsin Mansley discusses the past, present and future of AI in drug discovery. She shares her thoughts on how AI technologies are best serving the drug discovery industry, how any limitations in the field are being tackled by innovations in technology and where the future of new drug discovery technologies look to be headed.

Introduction

For drug discovery, there are three key areas of chemistry in which artificial intelligence (AI) technologies can be applied: generative chemistry, synthesis planning and compound property prediction. Together, these cover which potential drug candidates could be considered, how to synthesise them, and whether they will have the required balance of properties to successfully meet the project’s objectives.

Read the full article

Want to use AI in your drug discovery projects?

Discover Cerella

Tamsin Mansley

Global Head of Application Science and President Optibrium Inc.

Profile

On-demand

Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning

Now, watch Matt Segall, PhD, CEO at Optibrium, as he introduces a real world case study where we applied deep learning to guide a project, in which potential compounds were displaying good activity profiles but the team wanted to improve their PK profile to achieve better efficacy.